Literature DB >> 15992947

Atrial septal defect closure in a patient with "irreversible" pulmonary hypertensive arteriopathy.

Markus Schwerzmann, Moiz Zafar, Peter R McLaughlin, Dean W Chamberlain, Gary Webb, John Granton.   

Abstract

The presence of irreversible pulmonary hypertension in patients with atrial septal defect (ASD) is thought to preclude shunt closure. We report the case of a woman with plexiform pulmonary arteriopathy secondary to an ostium secundum ASD who was able to successfully undergo percutaneous shunt closure following therapy with chronic intravenous prostacyclin (Flolan). One year after closure, the patient was weaned off Flolan over a period of 7 months following the institution of oral Bosentan therapy. Our case illustrates how aggressive vasodilator therapy with prostaglandins may be capable of reducing pulmonary artery pressure and permitting shunt closure in a patient once considered to have "inoperable" pulmonary arteriopathy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15992947     DOI: 10.1016/j.ijcard.2005.05.062

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  17 in total

Review 1.  Pulmonary hypertension complicating congenital heart disease.

Authors:  J Eduardo Rame
Journal:  Curr Cardiol Rep       Date:  2009-07       Impact factor: 2.931

2.  The short- and medium-term results of transcatheter closure of atrial septal defect with severe pulmonary arterial hypertension.

Authors:  Zhi-wei Huang; Zhi-xin Fan; Jian-tao Sun; Wei-min Li; Yan-qing Gao; Yi-hua Quan; Ya-ming Geng; Yan-yan Niu; Bing-xiang Wu
Journal:  Heart Vessels       Date:  2011-09-17       Impact factor: 2.037

3.  Improvement of pulmonary arterial hypertension following medication and shunt closure in a BMPR2 mutation carrier with atrial septal defect.

Authors:  Hiroshi Suzuki; Haruo Hanawa; Tsukasa Torigoe; Seiichi Sato
Journal:  J Cardiol Cases       Date:  2017-04-26

4.  Atrial Septal Defect Closure with Occlutech® ASD Fenestrated Device in a Child with Severe Pulmonary Hypertension.

Authors:  Francisco Gonzalez-Barlatay; Anne Fournier; Marie-Josée Raboisson; Nagib Dahdah
Journal:  Pediatr Cardiol       Date:  2016-11-21       Impact factor: 1.655

Review 5.  "Treat and repair" strategy for shunt lesions: a critical review.

Authors:  Balaji Arvind; Jay Relan; Shyam S Kothari
Journal:  Pulm Circ       Date:  2020-04-09       Impact factor: 3.017

Review 6.  Surgical treatment for adult congenital heart disease: consideration for indications and procedures.

Authors:  Kozo Matsuo; Masashi Kabasawa; Soichi Asano; Shigeru Tateno; Yasutaka Kawasoe; Yoshitomo Okajima; Naoki Hayashida; Hirokazu Murayama
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-11-08

7.  Device closure of a large atrial septal defect in a patient with severe pulmonary arterial hypertension after 1 year use of an oral endothelin receptor antagonist.

Authors:  In Hyun Jung; Sang Yun Lee; Sook Jin Lee; Joo Young Lee; Nam Jin Park; Dea Sung Ahn; Jae Hoon Jung; Dong Hee Shin; Dal Soo Lim
Journal:  J Cardiovasc Ultrasound       Date:  2013-09-30

Review 8.  Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome.

Authors:  Nazzareno Galie; Alessandra Manes; Massimiliano Palazzini; Luca Negro; Alessandro Marinelli; Simona Gambetti; Elisabetta Mariucci; Andrea Donti; Angelo Branzi; Fernando M Picchio
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Successful two-stage correction of ventricular septal defect and patent ductus arteriosus in a patient with fixed pulmonary hypertension.

Authors:  Aysenur Pac; Tugcin Bora Polat; Kerem Vural; Mustafa Pac
Journal:  Pediatr Cardiol       Date:  2009-10-08       Impact factor: 1.655

Review 10.  Atrial septal defect and exercise capacity: value of cardio-pulmonary exercise test in assessment and follow-up.

Authors:  Pascal Amedro; Sophie Guillaumont; Charlene Bredy; Stefan Matecki; Arthur Gavotto
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.